title: Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema.
abstract: BACKGROUND
  Intravitreal application of triamcinolone and bevacizumab in Coats' disease with macular edema to improve visual outcome.
  
  
  METHODS
  Testing of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography, fluorescein angiography, 30° perimetry, and full-field electroretinography were performed at initial and follow-up visits. Medical treatment consisted of intravitreal injection of 1.25 mg bevazicumab and 1.25 mg triamcinolone, followed by intravitreal injections of 1.25 mg bevazicumab at weeks 4 and 10. Follow-up was 87 weeks.
  
  
  RESULTS
  Perimetric results, including a temporal absolute scotoma and reduced electroretinographic amplitudes (photopic and scotopic conditions), did not significantly change during the follow-up, but foveal retinal thickness decreased from 505 μm to 212 μm, and BCVA increased from 0.3 at baseline to 1.25 and remained stable during subsequent follow-up.
  
  
  CONCLUSIONS
  Combined intravitreal treatment with bevacizumab and triamcinolone resulted in significant decrease of central retinal thickness and improved visual acuity in this case report. Severe local or systemic side-effects were not observed.
authors.affiliation: University Eye Hospital, University Clinics Muenster, Domagkstr. 15, 48129, Muenster, Germany.
authors.forename: Michael R R
authors.initials: MR
authors.lastname: Böhm
authors.forename: Constantin E
authors.initials: CE
authors.lastname: Uhlig
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D004596:Electroretinography; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009887:Ophthalmoscopy; D012160:Retina / Q000187:drug effects / Q000473:pathology; D058456:Retinal Telangiectasis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity / Q000187:drug effects; D058609:Visual Field Tests
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide